Improving outcomes in AL amyloidosis
Transcript: Treatments for AL amyloidosis
Professor Giovanni Palladini
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Well, first of all there are differences amongst countries. So for instance, in Italy, daratumumab is approved, but we don't have access to this. So what I would recommend is to work on accessibility, each one in their own countries and so that we can grant access to the broadest possible number of patients. And this is different in each country. But what we have already been... What we have always been suggesting in this disease is that all the patients should be enrolled in clinical trials.
For instance, there are investigation and treatments that can be started upfront even in patients receiving the standard of care. In AL amyloidosis, we have only discussed anti-plasma cell agents so far but there are agents that can target deposits. So whenever possible it is important to enrol patients in clinical trials. And the for instance trials upfront that are investigating the role of passive immunotherapy on amylo deposits are very interesting. And of course in the relapse refractory setting is even more important to enrol patients in clinical trials. So you would say work on drug accessibility with your national agencies and but remember to enrol your patients in clinical trials whenever possible. We have just entered the evidence based medicine in AL amyloidosis but there is still much to do.
Developed independently by EPG Health, which received an educational grant from Alexion, awarded to EPG Health to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event